GIFT Nifty 🇮🇳: (+55, 26017)
Market Recap:
Nifty closed the week gone by with a strong, decisive gains, reinforcing the view that bullish momentum may soon become the new normal on Dalal Street.
The positive takeaway from Friday’s trading was that Nifty gained for 5th-straight day.
Bank Nifty was up for 6th straight day.
The Road Ahead:
Cheer returns to Dalal Street!
Jubilant sentiments are expected as the NDA’s Bihar victory energizes the market mood.
Our call of the day suggests bullish momentum may soon become the new normal on Dalal Street.
The Biggest Catalysts:
1) NDA landslide victory in Bihar, reinforcing political stability and market confidence.
2) India’s retail inflation sliding to a record 0.25% in October, well below the RBI’s tolerance band — strengthening hopes for a December rate cut.
3) US–India Trade Deal Hopes.
4) US Government Shutdown has finally ended.
5) Crude oil futures remain depressed as OPEC signaled a comfortable supply outlook.
The Biggest Headwinds:
FIIs sell in Friday’s bullish session to the tune of Rs. 4968.20 Crores.
This November month, FIIs have already sold to the tune of Rs. 13652.70 Cr.
Technically Speaking:
Technically speaking, Nifty is signalling a massive breakout on the upside — the benchmark should hit its all-time-high (26277.35) sooner than later.
The Gyan Mantra is to stay optimistic as long as Nifty holds above the 25,600-support zone — dips remain buying opportunities in the near term.
The Next Big Catalyst: This week, all eyes will be on the FOMC Minutes from the latest meeting to trickle in this Thursday, November 20th.
The minutes will offer deeper insight into the Federal Reserve’s thinking after it lowered the federal funds rate by 25 bps at its October 2025 meeting, bringing the target range to 3.75%–4.00%.
STOCKS IN SPOTLIGHT:
1) Glenmark Pharma Q2 PAT climbs 72% YoY to Rs 610 cr on 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25.
2) Kotak Mahindra Bank announced that its board is scheduled to meet on Friday, 21 November 2025, to consider a proposal for sub-division (split) of its existing fully paid-up equity shares having face value of Rs 5 each
Bottom Line:
The recent phase of turbulence and hesitation has receded.
Sentiment are improving, supported by rising expectations of rate cuts, fuelled by encouraging cooling CPI inflation that rekindles optimism and strengthens the market’s upward bias
Long Story Short: Animal spirits are back on Dalal Street.
Now, before we get into detail of today’s trading session, here is the preferred trade on Nifty and Bank Nifty:
Nifty (25910): Buy at CMP. Stop 25571. Targets 26277/26500. Aggressive targets at 26900-27100 zone.
Bank Nifty (58518): Buy at CMP. Stop at 57051. Targets 58907/59330. Aggressive targets at 59900-60300 zone.
Our chart of the day is bullish on BEL, SUN PHARMA and NYKAA on any early excessive intraday weakness with an interweek/Intermonth perspective.
The 1 Stock to Buy Right Now: Buy BEL (CMP 427): Buy at CMP. Stop at 412. Targets 439/446. Aggressive targets at 461. (Interweek Strategy). Rationale: Momentum Play. Signalling a massive breakout on the upside. Key interweek support 399. Major hurdles only at 439 mark. The stock is signaling a massive breakout on the upside. 200-DMA at 336.
Disclaimer/ Disclosure: The investments & trading ideas recomended in the market analysis, research reports, etc. may not be suitable for all investors. This article or data points does not construe investment advice as stock market investments are subject to market risks so please refer to your financial consultant advice before Investing or trading. All information is a point of view, and is for educational, Learning and informational use only. The author or the group admin accepts no liability for any interpretation of articles or comments on this platform being used for actual investments. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investors must make their own investment decisions based on their specific investment objectives, goals and financial position only by after consulting with registered market intermediaries.